IN THE CLAIMS

Please amend the claims as follows:

1-10. (Cancelled)

11. (Currently Amended) ~~A punctal plug~~ An ocular implant comprising:

~~a plug body~~ an implant body, including a porous or absorbent material, the [[plug]] implant body ~~sized and shaped for at least partial insertion into a lacrimal punctum and~~ extending from a proximal end portion, configured to seat at or near a lacrimal punctum when implanted, to a distal end portion, configured for insertion through the lacrimal punctum into a lacrimal canaliculus when implanted; and

an active agent disposed [[substantially]] entirely throughout ~~an exterior surface~~ the porous or absorbent material of the [[plug]] implant body ~~from approximately the proximal end portion to approximately the distal end portion~~, the active agent ~~configured to provide~~ delivered on a sustained release basis to tissue at or near one or both of a first location proximal to an eye or a second location distal to the eye ~~nasolacrimal system of a subject~~ via an ~~exposed medication-discharging supply~~ exterior surface portion of the implant body.

12. (Cancelled)

13. (Withdrawn - Currently Amended) The ~~punctal plug~~ ocular implant of claim 11, wherein the distal end portion of the [[plug]] implant body includes a stem, the stem configured to insert into [[a]] the lacrimal canaliculus ~~of the subject~~ and including the ~~exposed medication-discharging supply of~~ exterior surface portion of the implant body releasing the active agent ~~at one or more external surfaces thereof~~.

14. (Currently Amended) The ~~punctal plug~~ ocular implant of claim 11, wherein the proximal end portion of the [[plug]] implant body includes an outer stopper structure ~~extending at least partially from or around an outer body surface and~~ configured to seat against the lacrimal

punctum, the outer stopper structure including the ~~exposed medication-discharging supply of~~ exterior surface portion of the implant body releasing the active agent ~~at one or more external surfaces thereof~~ and having a size greater than an aperture size of the lacrimal punctum.

15. (Currently Amended) The ~~punctal plug~~ ocular implant of claim 11, wherein the active agent includes a medicine.

16. (Withdrawn – Currently Amended) The ~~punctal plug~~ ocular implant of claim 15, wherein the active agent includes a medicine selected from the group comprising: topical prostaglandin; latanoprost; travaprost; bimataprost; a medication for a treatment for corneal infections; ciprofloxacin; moxifloxacin; gatifloxacin; a systemic medication; a mediation for treating hypertension; atenolol; nifedipine; hydrochlorothiazide; cyclosporine; and olopatadine.

17. (Currently Amended) The ~~punctal plug~~ ocular implant of claim 11, wherein the active agent includes a medication for treatment of an eye.

18. (Withdrawn – Currently Amended) The ~~punctal plug~~ ocular implant of claim 11, wherein the [[plug]] implant body includes a lumen extending from the proximal end portion to the distal end portion, the lumen configured for a passage of tear fluid therethrough.

19. (Withdrawn – Currently Amended) The ~~punctal plug~~ ocular implant of claim 18, wherein ~~the exposed medication-discharging supply of~~ the sustained release of the active agent to tissue at or near the second location distal to the eye is via an interior lumen surface portion of the implant body ~~disposed on at least one portion of the lumen wall, the active agent configured to treat the nasolacrimal system~~.

20. (Cancelled)

21. (Currently Amended) The ~~punctal plug~~ ocular implant of claim 11, wherein the ~~exposed medication-discharging supply of~~ exterior surface portion of the implant body releasing the

active agent is disposed ~~on at least one external surface of~~ at or near the proximal end portion of the [[plug]] implant body, the active agent configured to treat the eye.

22. (Currently Amended) The ~~punctal plug~~ ocular implant of claim 21, wherein the ~~exposed medication-discharging supply of~~ exterior surface portion of the implant body releasing the active agent is configured to provide the sustained release to tissue at or near the eye for a time period ~~of at least about~~ between 3-6 months after implant.

23. (Withdrawn – Currently Amended) The ~~punctal plug~~ ocular implant of claim 21, wherein the ~~exposed medication-discharging supply of~~ exterior surface portion of the implant body releasing the active agent ~~includes~~ is in the form of one or more agent-discharging bands.

24. (Withdrawn – Currently Amended) The ~~punctal plug~~ ocular implant of claim 11, wherein the ~~exposed medication-discharging supply of~~ exterior surface portion of the implant body releasing the active agent is disposed ~~on at least one external surface of~~ at or near the distal end portion, the active agent configured to treat, at least in part, the nasolacrimal system.

25. (Withdrawn – Currently Amended) The ~~punctal plug~~ ocular implant of claim 24, wherein the ~~exposed medication-discharging supply of~~ exterior surface portion of the implant body releasing the active agent ~~includes~~ is in the form of one or more agent-discharging bands.

26. (Withdrawn – Currently Amended) The ~~punctal plug~~ ocular implant of claim 11, wherein the ~~exposed medication-discharging supply of~~ exterior surface portion of the implant body releasing the active agent is disposed on all ~~external~~ exterior surfaces of the [[plug]] implant body.

27. (Withdrawn – Currently Amended) The ~~punctal plug~~ ocular implant of claim 11, wherein the distal end portion of the [[plug]] implant body includes an inner stopper structure, the inner stopper structure configured to at least partially secure an implant location of the [[plug]] implant body.

28. (Withdrawn – Currently Amended) The ~~punctal plug~~ ocular implant of claim 13, wherein the ~~exposed medication-discharging supply of~~ exterior surface portion of the implant body releasing the active agent is configured to provide the sustained release to tissue of the canaliculus wall.

29. (Currently Amended) The ~~punctal plug~~ ocular implant of claim 14, wherein the outer stopper structure is configured to completely seal the lacrimal punctum against a flow of tear fluid therethrough.

30. (Currently Amended) ~~A punctal plug~~ An ocular implant comprising:

~~a plug~~ an implant body, including a porous or absorbent material, sized and shaped for at least partial insertion into a lacrimal [[punctum]] canaliculus; and

the implant body incorporating an active agent from a proximal end portion of the porous or absorbent material included in the implant body, configured to seat at or near a lacrimal punctum when implanted, to a distal end portion of the porous or absorbent material included in the implant body, configured for insertion through the lacrimal punctum into the lacrimal canaliculus when implanted, ~~an exposed medication-discharging supply of an active agent at least partially disposed on at least one external surface of the plug body~~, the ~~exposed medication-discharging supply~~ active agent ~~configured to provide~~ delivered ~~a sustained release of the active agent~~ to tissue at or near one or both of a first location proximal to an eye or a second location proximal a nasolacrimal system ~~for a time period of at least about 3 months after implant~~.

31. (Currently Amended) The ~~punctal plug~~ ocular implant of claim 30, wherein ~~the exposed medication-discharging supply of~~ an exterior surface of the implant body at the proximal end portion releases the active agent ~~is disposed on at least one surface of a proximal end portion of the plug body, the active agent configured~~ to treat the eye.

32. (Withdrawn – Currently Amended) The ~~punctal plug~~ ocular implant of claim 30, wherein ~~the exposed medication-discharging supply of~~ an exterior surface of the implant body at

the distal end portion releases the active agent ~~is disposed on at least one surface of a distal end portion of the plug body, the active agent configured~~ to treat the nasolacrimal system.

33. (Currently Amended) The ~~punctal plug~~ ocular implant of claim 30, wherein [[a]] the distal end portion of the [[plug]] implant body includes an inner stopper structure configured to at least partially secure an implant location of the [[plug]] implant body.

34. (Currently Amended) The ~~punctal plug~~ ocular implant of claim 30, wherein the entire [[plug]] implant body is substantially saturated with the active agent.

35. (Withdrawn – Currently Amended) The ~~punctal plug~~ ocular implant of claim 34, wherein ~~the exposed medication discharging supply of the agent is disposed on~~ all ~~external~~ exterior surfaces of the [[plug]] implant body release the active agent.

36. (Withdrawn – Currently Amended) The ~~punctal plug~~ ocular implant of claim 30, wherein the active agent includes a medicine selected from the group comprising: topical prostaglandin; latanoprost; travaprost; bimataprost; a medication for a treatment for corneal infections; ciprofloxacin; moxifloxacin; gatifloxacin; a systemic medication; a mediation for treating hypertension; atenolol; nifedipine; hydrochlorothiazide; cyclosporine; and olopatadine.

37. (New) The ocular implant of claim 11, wherein the implant body is substantially inert.

38. (New) The ocular implant of claim 11, wherein the active agent includes a medication for the treatment of glaucoma.

39. (New) The ocular implant of claim 38, wherein the medication for the treatment of glaucoma includes a topical prostaglandin derivative.

40. (New) The ocular implant of claim 39, wherein the topical prostaglandin derivative includes at least one of latanoprost, travaprost, or bimataprost.

41. (New) The ocular implant of claim 30, wherein the active agent is administered on a sustained release basis for a time period of between 3-6 months after implant.

42. (New) The ocular implant of claim 30, wherein the active agent includes a medication for the treatment of glaucoma.

43. (New) The ocular implant of claim 42, wherein the medication for the treatment of glaucoma includes a topical prostaglandin derivative.

44. (New) The ocular implant of claim 43, wherein the topical prostaglandin derivative includes at least one of latanoprost, travaprost, or bimataprost.